Brazil now has roughly fifty-five million pet dogs — more per capita than the United States, and more in absolute terms than any country except China. The pet care market has been growing at double-digit rates for the last decade, and the geographic concentration around São Paulo and Rio de Janeiro means that a single metropolitan area accounts for more dog owners than several mid-sized European countries combined. None of which makes it easy to bring a novel veterinary therapeutic into the country.

The Brazilian regulatory pathway for novel veterinary drugs runs through MAPA (the agriculture ministry) and historically requires either local clinical data or evidence of approval in a recognized reference market. For a longevity drug, "local clinical data" is essentially impossible to generate ahead of foreign approval — no Brazilian institution is going to enroll dogs in a long-duration trial of an unapproved compound — so the realistic pathway is import authorization following EU or U.S. approval, then a domestic registration process that adds eighteen to twenty-four months on top.

Local veterinary associations have been quietly lobbying for a streamlined process, modelled on the recent reforms to human oncology drug imports, but the political calendar makes near-term legislative action unlikely. The most plausible accelerator would be MAPA exercising its existing administrative discretion to recognize an EMA or FDA-CVM approval as a valid basis for domestic registration without a full re-review — a move the agency has used selectively in the past for human medicines but not yet for veterinary ones.

For Brazilian owners following this story, the practical implication is that the prescribing pathway is likely to lag the major markets by close to two years. That gap creates predictable pressure points: a robust grey market for personally imported supply, owners traveling to Argentina or Uruguay to enroll their dogs in regional access programmes, and a wave of unregulated supplement products attempting to fill the void.

We'll track the MAPA timeline alongside the FDA and EMA timelines in the regulatory-status section, with a Brazil-specific update whenever there's movement on either the import pathway or any of the bilateral recognition discussions currently underway.